Corrigendum: IL-17 promotes angiogenic factors IL-6, IL-8, and vegf production via stat1 in lung adenocarcinoma (Scientific Reports (2016) 6 (36551) DOI: 10.1038/srep36551);IL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production via Stat1 in Lung Adenocarcinoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Huang, Qi ^a   Duan, Limin ^a   Qian, Xin ^b   Fan, Jinshuo ^a   Lv, Zhilei ^a   Zhang, Xiuxiu ^a   Han, Jieli ^a   Wu, Feng ^a   Guo, Mengfei ^a   Hu, Guorong ^a   Du, Jiao ^c   Chen, Caiyun ^d   Jin, Yang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c XIAMEN UNIVERSITY   (China)

^d First Hosp of Xi'an Jiaotong Univ   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

A-549 CELL LINE; ADENOCARCINOMA; ANIMAL; HUMAN; LUNG TUMOR; MALE; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; TUMOR CELL LINE;

A549 CELLS; ADENOCARCINOMA; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL LINE, TUMOR; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; INTERLEUKIN-8; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; STAT1 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84994389251     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep39566     Document Type: Erratum

References (43)

1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J Clin. 65, 87-108 (2015).
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J Clin. 65, 5-29 (2015).
3. Hensing, T., Chawla, A., Batra, R. & Salgia, R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 799, 85-117, doi: 10.1007/978-1-4614-8778-4-5 (2014).
4. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
5. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
6. Sharma, S., Sharma, M. C. & Sarkar, C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology. 46, 481-489, doi: 10.1111/j.1365-2559.2005.02142.x (2005).
7. Numasaki, M. et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 175, 6177-6189 (2005).
8. Pan, B. et al. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep. 5, 16053, doi: 10.1038/srep16053 (2015).
9. Engels, E. A. Inflammation in the development of lung cancer: epidemiological evidence. Expert. Rev. Anticanc. 8, 605-615, doi: 10.1586/14737140.8.4.605 (2008).
10. Crino, L. & Metro, G. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev. 23, 79-91, doi: 10.1183/09059180.00008913 (2014).
11. Basu, R., Hatton, R. D. & Weaver, C. T. The Th17 family: flexibility follows function. Immunol Rev. 252, 89-103, doi: 10.1111/ imr.12035 (2013).
12. Murugaiyan, G. & Saha, B. Protumor vs Antitumor Functions of IL-17. J. Immunol. 183, 4169-4175, doi: 10.4049/jimmunol.0901017 (2009).
13. Reppert, S., Koch, S. & Finotto, S. IL-17A is a central regulator of lung tumor growth. Oncoimmunology. 1, 783-785, doi: 10.4161/ Onci.19735 (2012).
14. Liu, L. X. et al. Interleukin-17 and Prostaglandin E2 Are Involved in Formation of an M2 Macrophage-Dominant Microenvironment in Lung Cancer. J Thorac Oncol. 7, 1091-1100, doi: 10.1097/Jto.0b013e3182542752 (2012).
15. Li, Q. et al. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol. Lett. 148, 144-150, doi: 10.1016/j. imlet.2012.10.011 (2012).
16. Li, Y. et al. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther. 12, 610-616, doi: 10.4161/cbt.12.7.16302 (2011).
17. Sundrud, M. S. & Trivigno, C. Identity crisis of Th17 cells: many forms, many functions, many questions. Semin Immunol. 25, 263-272, doi: 10.1016/j.smim.2013.10.021 (2013).
18. Wang, M., Wang, L., Ren, T., Xu, L. & Wen, Z. IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells. Cancer Biol Ther. 14, 155-163, doi: 10.4161/cbt.22955 (2013).
19. Kennedy, C. L. et al. The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. J Pathol. 225, 255-264, doi: 10.1002/path.2933 (2011).
20. Gu, F. M. et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol. Cancer. 10, 150, doi: 10.1186/1476-4598-10-150 (2011).
21. Huang, Q. et al. The effect of proinflammatory cytokines on IL-17RA expression in NSCLC. Med Oncol. 31, 144, doi: 10.1007/ s12032-014-0144-z (2014).
22. Zhou, X. et al. TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer. Plos One. 8, e80576, doi: 10.1371/journal.pone.0080576 (2013).
23. Huang, Q. et al. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer. J Cancer Res Clin Oncol. 142, 263-272, doi: 10.1007/s00432-015-2040-0 (2015).
24. Miyahara, Y. et al. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA 105, 15505-15510, doi: 10.1073/pnas.0710686105 (2008).
25. Kato, T. et al. Expression of IL-17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun. 282, 735-738, doi: 10.1006/ bbrc.2001.4618 (2001).
26. Zhang, J. P. et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 50, 980-989, doi: 10.1016/j.jhep.2008.12.033 (2009).
27. Alexandrakis, M. G. et al. Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med. 17, 412-416, doi: 10.1016/j.ejim.2006.02.012 (2006).
28. Liu, J. et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem. Biophys. Res. Commun. 407, 348-354, doi: 10.1016/j.bbrc.2011.03.021 (2011).
29. Gu, F. M. et al. Intratumoral IL-17(+ ) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 19, 2506-2514, doi: 10.1245/s10434-012-2268-8 (2012).
30. Dankbar, B. et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 95, 2630-2636 (2000).
31. Yuan, A. et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 162, 1957-1963, doi: 10.1164/ ajrccm.162.5.2002108 (2000).
32. Bremnes, R. M., Camps, C. & Sirera, R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 51, 143-158, doi: 10.1016/j.lungcan.2005.09.005 (2006).
33. Miossec, P. & Kolls, J. K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug. Discov. 11, 763-776, doi: 10.1038/ nrd3794 (2012).
34. Wang, L. et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 206, 1457-1464, doi: 10.1084/ jem.20090207 (2009).
35. Li, Y. et al. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer. Biol. Ther. 12, 610-616 (2011).
36. Peters, A. & Yosef, N. Understanding Th17 cells through systematic genomic analyses. Curr. Opin. Immunol. 28, 42-48, doi: 10.1016/j.coi.2014.01.017 (2014).
37. Subramaniam, S. V., Cooper, R. S. & Adunyah, S. E. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem. Biophys. Res. Commun. 262, 14-19, doi: 10.1006/bbrc.1999.1156 (1999).
38. Shi, X. et al. IL-17A upregulates keratin 17 expression in keratinocytes through STAT1-and STAT3-dependent mechanisms. J Invest Dermatol. 131, 2401-2408, doi: 10.1038/jid.2011.222 (2011).
39. Zhang, E. et al. Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1alpha, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells. Plos One. 9, e103440, doi: 10.1371/journal. pone.0103440 (2014).
40. Demyanets, S. et al. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2-and STAT1/STAT3-dependent pathways and is attenuated by interferon-gamma. Basic. Res. Cardiol. 106, 217-231, doi: 10.1007/s00395-010-0141-0 (2011).
41. Zarogoulidis, P., Yarmus, L. & Zarogoulidis, K. New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer. Ther. Deliv. 4, 1221-1223, doi: 10.4155/tde.13.95 (2013).
42. Rafrafi, A. et al. Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: A case control study. Hum. Immunol. 74, 1368-1374, doi: 10.1016/j.humimm.2013.06.033 (2013).
43. Alevizakos, M., Kaltsas, S. & Syrigos, K. N. The VEGF pathway in lung cancer. Cancer. Chemother. Pharmacol. 72, 1169-1181, doi: 10.1007/s00280-013-2298-3 (2013).